Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalie Bellini

Nurse Practitioner, Family Mayfield Heights, OH Nurse Practitioner

NPI 1619436664 CMS profile 10500677

5885 Landerbrook Dr Ste 100, Mayfield Heights, OH 44124

Open in the dashboard

General payments

$582,141

1,241 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Bellini of Mayfield Heights, OH is reported in the CMS Open Payments database as having received $582,141 across 1,241 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $167,025 291
2024 General $234,038 332
2023 General $64,214 175
2022 General $74,958 218
2021 General $41,905 225

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Bellini
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Natalie Bellini were reported at $167,025. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Natalie Bellini Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $41,905 $124 $35–$379 $132
2022 $74,958 $141 $44–$430 $149
2023 $64,214 $154 $49–$476 $160
2024 $234,038 $165 $51–$504 $164
2025 $167,025 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sanofi-Aventis U.S. LLC $198,710 282 payments
  2. Abbott Laboratories $181,409 298 payments
  3. Embecta Corp. $93,904 46 payments
  4. Sequel Med Tech, LLC $32,885 40 payments
  5. Genzyme Corporation $13,403 10 payments
  6. Medtronic, Inc. $11,576 36 payments
  7. Corcept Therapeutics $11,034 46 payments
  8. Mannkind Corporation $9,295 54 payments
  9. Dexcom, Inc. $5,564 46 payments
  10. Ascensia Diabetes Care US Inc. $5,030 5 payments
  11. Other $19,329 378 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $192,817 130 payments
  2. Consulting Fee $168,888 55 payments
  3. Travel and Lodging $99,376 240 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $92,352 87 payments
  5. Food and Beverage $28,482 721 payments
  6. Education $133 6 payments
  7. Long term medical supply or device loan $50 1 payment
  8. Gift $43 1 payment
Products named General payments · program years 2021–2025
  1. TZIELD $196,296 251 payments
  2. FreeStyle Libre 3 $71,532 120 payments
  3. FreeStyle Libre 2 $38,278 78 payments
  4. FreeStyle Libre Pro $38,104 48 payments
  5. FREESTYLE LIBRE $33,000 45 payments
  6. TWIIST $32,799 39 payments
  7. Korlym $11,034 46 payments
  8. AFREZZA $9,295 54 payments
  9. DEXCOM G7 GSS (161) $4,553 6 payments
  10. DEXCOM STELO GLUCOSE BIOSENSOR $4,303 5 payments
  11. Other $21,356 575 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,770

Median for Nurse Practitioner: 389

Drug cost

$1,168,656

Median for Nurse Practitioner: $21,885

Branded share of claims

84%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 283 $369,638
Trulicity Dulaglutide Brand 164 $197,190
Jardiance Empagliflozin Brand 136 $136,965
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 62 $82,636
Mounjaro Tirzepatide Brand 61 $81,698
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 37 $43,619
Humalog Kwikpen U-100 Insulin Lispro Brand 92 $26,876
Farxiga Dapagliflozin Propanediol Brand 27 $25,449
Januvia Sitagliptin Phosphate Brand 31 $25,143
Tresiba Flextouch U-100 Insulin Degludec Brand 29 $21,603

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$14,979

Medicare's payments for the services billed

Medicare patients

99

Average age 69

Services billed

364

52 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 44%
Ischemic heart disease 39%
Depression 26%
Heart failure 21%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
$86,660 — —
Korlym
$6,713 — —
AFREZZA
$358 — —
MOUNJARO
$186 61 —
Kerendia
$85 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,241 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record